Prelude Therapeutics Inc (PRLD) Stock Price, Quote & News

Company Profile

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin...

Industry: Biotechnology

Sector: Healthcare

Phone: 302 467 1280

Website: preludetx.com

Address:

175 Innovation Boulevard, Wilmington, United States

LabPsycho Oct. 24 at 5:23 PM

$PRLD My calculations suggest this will regroup here around $1.60-$1.64 pause then lunge to $1.89 or above.

0 · Reply

GODOFUSD Oct. 23 at 5:46 PM

$BMEA I’m bullish on $BMEA’s future, but without partnerships, shareholders are stuck paying! Good data won’t save us from more dilutions. Look at $CAMP, $PRLD or others with partners absorbing cash burn. Land a deal soon, and we’re moon-bound; otherwise, more dilution will tank us to $0.50!

0 · Reply

exp8triot Oct. 22 at 2:33 PM

$PRLD wanna know what it takes to be a millionaire? Buy at these levels $3/share next month. $5/share by March

0 · Reply

LabPsycho Oct. 22 at 12:48 PM

$NRIX @outlawinvestor1 If you posted and updated comparison table, $PRLD would move close to the top as 1 month gainers.

1 · Reply

Tradelearner2022 Oct. 22 at 5:00 AM

$PRLD - Not able to understand why it ripped today ?

1 · Reply

StockScanners Oct. 22 at 2:08 AM

$PRLD keep watch if this holds above 1.40

0 · Reply

elitechrisvp Oct. 21 at 8:13 PM

$PRLD perky perky 😁👍

0 · Reply

LabPsycho Oct. 21 at 7:35 PM

$PRLD Right on target - hit the predicted $1.64 today (see below). More ($1.89) to come after a pull back?

1 · Reply

outlawinvestor1 Oct. 21 at 6:40 PM

$PRLD what in the world is happening with prelude today? glad i placed a small bet, but now kicking myself that i didn't invest more.

1 · Reply

exp8triot Oct. 21 at 5:33 PM

$PRLD volume pickin up a bit ..on track for 1 million+ shares traded today..

0 · Reply

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

Aug 14, 2025, 7:00 AM EDT - 2 months ago

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 2, 2025, 7:30 AM EDT - 5 months ago

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

May 6, 2025, 4:05 PM EDT - 6 months ago

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 1, 2025, 7:30 AM EDT - 6 months ago

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

Apr 25, 2025, 4:05 PM EDT - 6 months ago

Prelude Announces Presentations at 2025 AACR Annual Meeting

Mar 10, 2025, 7:30 AM EDT - 8 months ago

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Mar 5, 2025, 7:30 AM EST - 8 months ago

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

$Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies$

Dec 11, 2024, 7:30 AM EST - 11 months ago

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Nov 27, 2024, 7:30 AM EST - 11 months ago

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

Sep 13, 2024, 10:00 AM EDT - 1 year ago

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Aug 12, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

May 9, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

May 7, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 9, 2024, 4:35 PM EDT - 1 year ago

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Mar 5, 2024, 4:45 PM EST - 1 year ago

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Feb 29, 2024, 4:05 PM EST - 1 year ago

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Feb 15, 2024, 4:05 PM EST - 1 year ago

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Dec 11, 2023, 9:34 AM EST - 2 years ago

Prelude Therapeutics Announces $25 Million Private Placement

Nov 1, 2023, 4:10 PM EDT - 2 years ago

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

Aug 29, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

May 31, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

May 17, 2023, 4:08 PM EDT - 2 years ago

Prelude Therapeutics Announces Launch of Proposed Public Offering

May 8, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

Apr 27, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

Apr 11, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Mar 15, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 15, 2023, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

Feb 9, 2023, 9:05 AM EST - 2 years ago

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

Nov 14, 2022, 8:00 AM EST - 3 years ago

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

Aug 9, 2022, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

May 10, 2022, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

Mar 16, 2022, 7:30 AM EDT - 3 years ago

Prelude Therapeutics Reports Full Year 2021 Financial Results

Mar 11, 2022, 8:00 AM EST - 3 years ago

Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

Mar 9, 2022, 8:05 AM EST - 3 years ago

Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting

Feb 11, 2022, 7:00 AM EST - 4 years ago

Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Jan 4, 2022, 7:00 AM EST - 4 years ago

Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

Nov 23, 2021, 7:00 AM EST - 4 years ago

Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference

Nov 12, 2021, 8:00 AM EST - 4 years ago

Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update

Nov 8, 2021, 9:00 AM EST - 4 years ago

Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor

Oct 7, 2021, 12:55 PM EDT - 4 years ago

Why Did Prelude Therapeutics Stock Tumble To 52-Week Low Today?

Oct 7, 2021, 9:00 AM EDT - 4 years ago

Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Aug 12, 2021, 7:30 AM EDT - 4 years ago

Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update

Jul 27, 2021, 12:32 PM EDT - 4 years ago

Why BofA Is Turning Bullish On Prelude Therapeutics

LabPsycho Oct. 24 at 5:23 PM

$PRLD My calculations suggest this will regroup here around $1.60-$1.64 pause then lunge to $1.89 or above.

0 · Reply

GODOFUSD Oct. 23 at 5:46 PM

0 · Reply

exp8triot Oct. 22 at 2:33 PM

$PRLD wanna know what it takes to be a millionaire? Buy at these levels $3/share next month. $5/share by March

0 · Reply

LabPsycho Oct. 22 at 12:48 PM

$NRIX @outlawinvestor1 If you posted and updated comparison table, $PRLD would move close to the top as 1 month gainers.

1 · Reply

Tradelearner2022 Oct. 22 at 5:00 AM

$PRLD - Not able to understand why it ripped today ?

1 · Reply

StockScanners Oct. 22 at 2:08 AM

$PRLD keep watch if this holds above 1.40

0 · Reply

elitechrisvp Oct. 21 at 8:13 PM

$PRLD perky perky 😁👍

0 · Reply

LabPsycho Oct. 21 at 7:35 PM

$PRLD Right on target - hit the predicted $1.64 today (see below). More ($1.89) to come after a pull back?

1 · Reply

outlawinvestor1 Oct. 21 at 6:40 PM

$PRLD what in the world is happening with prelude today? glad i placed a small bet, but now kicking myself that i didn't invest more.

1 · Reply

exp8triot Oct. 21 at 5:33 PM

$PRLD volume pickin up a bit ..on track for 1 million+ shares traded today..

0 · Reply

LabPsycho Oct. 21 at 4:54 PM

$PRLD If one zooms in on the molecular dynamic simulation I posted below, they can see with atomic resolution residues of the protein that may interact with various moieties of the drug. Here just for kicks, I show the putative (lots of guessing from patent and literature research which of the hundreds of variants of $PRLD 's PRT7732 might be but I think is is at least a reasonable approximation) showing ASN, TYR and LEU in close proximity to the drug. One could refine the drug further to enhance or repel such interactions depending on the goal. Big advantage for me of doing these simulations is spilling pizza grease on the keyboard rather than in the test tubes - Ha

0 · Reply

LabPsycho Oct. 21 at 4:34 PM

$PRLD @pchr 1. Several potential upcoming milestones 2. Molecular glues / degraders seem to be regaining traction (i.e. $CCCC decent results and several big pharma collaborations and $GLUE recent huge partnership with Novartis with tons of $$$ (120M $ UPFRONT) 3. $PRLD fusing PROTAC / molecular degraders with antibodies (great idea IMO with some likely specialized applications) 4. CEO purchased shares about a year ago 5. Generally drifting up with many other beat down biotechs. 6. Recent phantom spike up to $1.91 (then full retrace) suggests wind of a (positive?) development a few weeks ago 7. My molecular dynamic simulation posted here a couple weeks ago (strong bias! LoL)

0 · Reply

Dizzier47 Oct. 21 at 4:24 PM

$PRLD still not 5$? miss me

0 · Reply

LabPsycho Oct. 21 at 4:02 PM

$PRLD inching up towards short-term predicted Target price of 1.64 then on to 1.9 as predicted below

1 · Reply

exp8triot Oct. 21 at 3:11 PM

$PRLD wiggle wiggle

0 · Reply

IsabelSims1079 Oct. 20 at 4:28 PM

$PRLD pioneering science; AITX pioneering automation — Steve Reinharz confirms a profitable quarter and strong year-end outlook.

0 · Reply

LabPsycho Oct. 15 at 6:01 PM

$PRLD Calculations suggest this has been cleaned out and shined up and ready for the move to $1.64, then + $1.89 IMO.

0 · Reply

Dizzier47 Oct. 14 at 7:03 PM

$PRLD 1$, 1,20$, 1,50$ or 2$ i do not care give me 15$ already stop teasing

1 · Reply

LabPsycho Oct. 9 at 2:34 PM

$GLUE Up and over $8 as predicted. I think $PRLD , another molecular glue / degrader company with upcoming clinical results, is next for a strong move.

2 · Reply

LabPsycho Oct. 6 at 10:19 PM

$PRLD @pchr 1. Several potential upcoming milestones 2. Molecular glues / degraders seem to be regaining traction (i.e. $CCCC decent results and several big pharma collaborations and $GLUE recent huge partnership with Novartis with tons of $$$ (120M $ UPFRONT) 3. $PRLD fusing PROTAC / molecular degraders with antibodies (great idea IMO with some likely specialized applications) 4. CEO purchased shares about a year ago 5. Generally drifting up with many other beat down biotechs. 6. My molecular dynamic simulation posted here a couple weeks ago (strong bias! LoL)

0 · Reply

pchr Oct. 4 at 6:38 PM

$PRLD could someone elaborate why are you bullish on this stock? Any incoming catalysts?

1 · Reply

elitechrisvp Oct. 1 at 2:06 PM

$XBI 👀 $IBRX $PRLD

0 · Reply

Market Cap	84.90M
Revenue (ttm)	7.00M
Net Income (ttm)	-127.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,816.71%
Debt to Equity Ratio	0.00

Volume	227,500
Avg Vol	269,776
Day's Range	N/A - N/A
Shares Out	56.60M
Stochastic %K	88%
Beta	1.28
Analysts	Sell
Price Target	$3.50